Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Central Nervous System Neoplasms × bemcentinib × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 1 Central Nervous System Neoplasms 1

Interventions

motexafin gadolinium 1 irinotecan sucrosofate 1 bemcentinib 1 Vincristine 1 Temozolomide 1 Rituximab 1 Radiotherapy 1 Radiation 1 Procarbazine 1 Postoperative Period 1 Pemetrexed 1 Methotrexate 1 Memantine 1 Irinotecan 1 Donepezil 1 Cytarabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Terminated

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡